An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen® (DAAO Inhibitor), as an Add-on Treatment for Schizophrenia in Adults
Phase of Trial: Phase II/III
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Sodium benzoate (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors SyneuRx International (Taiwan) corp
- 14 Jul 2017 According to a SyneuRx International media release, 3 subjects have been randomized from the 11 subjects screened into this trial within a short period of time.
- 06 Apr 2017 Status changed from not yet recruiting to recruiting.
- 19 Mar 2017 Planned initiation date changed from 1 Jan 2015 to 29 Mar 2017.